MedTrace Logo

Pityriasis Lichenoides Chronica, Role of Streptococcal Infection and Azithromycin

NCT03831269 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-02-05

No results posted yet for this study

Summary

Primary outcome:

The primary outcome at end of study (EOS) is to compare the therapeutic efficacy of Azithromycin in the treatment of pityriasis lichenoides chronica (PLC) with that of a well-documented line of therapy namely narrow band ultra violet B (nbUVB).

Secondary outcomes:

1\. To identify the possibility of streptococcal throat infection as a possible underlying etiology in PLC.

Conditions

  • Pityriasis Lichenoides

Interventions

DRUG

Azithromycin

Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study

OTHER

nbUVB

The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2020-06-30
Completion
2020-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03831269 on ClinicalTrials.gov